| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-01-03 | KU-046 | Alzheimer’s disease | 1 | Kareus Therapeutics (Switzerland) | Neurodegenerative diseases |
| 2013-01-00 | PRO045 | Duchenne muscular dystrophy |
2b | Prosensa (The Netherlands) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2012-12-27 | nepicastat (SYN117) | post-traumatic stress disorder (PTSD) |
2 | Biotie Therapies (Finland) | Mental diseases |
| 2012-12-21 | cadazolid | Clostridium difficile associated diarrhea (CDAD) |
2 | Actelion (Switzerland) | Infectious diseases |
| 2012-12-21 | DPK-060 | external otitis (swimmers ear) | 2 | Pergamum (Sweden) | Infectious diseases |
| 2012-12-19 | anti-NKG2D (NN8555) | Crohn's disease | 2a | Novo Nordisk (Denmark) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2012-12-18 | VB-111 (ofranergene obadenovec) | ovarian cancer | 1-2 | VBL Therapeutics (Israel) | Cancer - Oncology |
| 2012-12-18 | ponesimod | psoriasis | 2 | Actelion (Switzerland) | Autoimmune diseases - Dermatological diseases |
| 2012-12-13 | fostamatinib | rheumatoid arthritis | 2b | AstraZeneca (UK) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2012-12-13 | PDC31 | preterm labour |
1 | PDC Biotech (Austria) | Women health |
| 2012-12-12 | resminostat (oral pan-histone deacetylase (HDAC) inhibitor) | advanced colorectal cancer | 1-2 | 4SC (Germany) | Cancer - Oncology |
| 2012-12-12 | V81444 (adenosine A2A receptor antagonist) | Parkinson’s Disease |
Receptor Occupancy study | Vernalis (UK) | Neurodegenerative diseases - CNS diseases |
| 2012-12-12 | rhLAMAN (Lamazym™) | alpha-mannosidosis |
3 | Zymenex (Denmark) | Rare diseases - Genetic diseases |
| 2012-12-11 | lirilumab or IPH2102/BMS-986015 | multiple myeloma |
1-2a | Innate Pharma (France) | Cancer - Oncology |
| 2012-12-11 | ABH001 | epidermolysis bullosa |
3 | Shire (UK-USA) | Rare diseases - Genetic diseases - Dermatological diseases |
| 2012-12-10 | elacytarabine | relapsed or refractory acute myeloid leukaemia (AML) | 2 | Clavis Pharma (Norway) | Cancer - Oncology |
| 2012-12-10 | Erwinaze® (asparaginase Erwinia chrysanthemi) | acute lymphoblastic leukemia (ALL) | Jazz Pharmaceuticals (Ireland) | Cancer - Oncology | |
| 2012-12-10 | SAR650984 (antiCD38 monoclonal antibody) | relapsed or refractory multiple myeloma | 1 | Sanofi (France) | Cancer - Oncology |
| 2012-12-09 | SAR302503 | myelofibrosis | 2 | Sanofi (France) | Cancer - Oncology - Blood diseases - Hematological diseases |
| 2012-12-08 | MabThera® (rituximab) | non-Hodgkin lymphoma | 3 | Roche (Switzerland) | Cancer - Oncology |
